Literature DB >> 26517625

Antibiotic susceptibility of diverse Mycobacterium abscessus complex strains in New South Wales, Australia.

Kyra Y L Chua1, Andrea Bustamante, Peter Jelfs, Sharon C-A Chen, Vitali Sintchenko.   

Abstract

Members of the Mycobacterium abscessus complex are emerging pathogens of increasing importance, causing both respiratory and soft tissue infections, but precise speciation is problematic. This study was performed to examine the subspecies and antibiotic susceptibility of M. abscessus complex isolates collected during 2013 at the statewide New South Wales Mycobacterium Reference Laboratory (NSW MRL), Australia. Mycobacterium abscessus subsp. abscessus accounted for more than half of all M. abscessus isolates (n = 24, 57.1%), and M. abscessus subsp. massiliense comprised the remainder of the isolates (n = 18, 42.9%). There were no M. abscessus subsp. bolletii isolates. The prevalence of antibiotic resistance to all antibiotics, apart from amikacin was high, with 26.3% of isolates being reliably susceptible to only amikacin. Most M. abscessus subsp. abscessus isolates (80%) demonstrated inducible clarithromycin resistance whereas the majority of M. abscessus subsp. massiliense isolates (94.4%) remained susceptible to clarithromycin. There was a good correlation between the erm(41) genotype and clarithromycin susceptibility results after 14 days of incubation for most isolates with only three exceptions. Further studies correlating in vitro susceptibility profiles with clinical outcomes of M. abscessus infections treated with combination antimicrobial therapy are warranted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26517625     DOI: 10.1097/PAT.0000000000000327

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  11 in total

1.  Whole-Genome Sequencing for Predicting Clarithromycin Resistance in Mycobacterium abscessus.

Authors:  Samuel Lipworth; Natasha Hough; Laura Leach; Marcus Morgan; Katie Jeffery; Monique Andersson; Esther Robinson; E Grace Smith; Derrick Crook; Tim Peto; Timothy Walker
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance of Mycobacterium abscessus to Imipenem.

Authors:  Siyuan He; Yuzhen Zou; Mengling Zhan; Qi Guo; Yongjie Zhang; Zhemin Zhang; Bing Li; Shaoyan Zhang; Haiqing Chu
Journal:  Infect Drug Resist       Date:  2020-08-18       Impact factor: 4.003

3.  Mycobacteriophages as Genomic Engineers and Anti-infective Weapons.

Authors:  Mark R Sullivan; Eric J Rubin; Charles L Dulberger
Journal:  mBio       Date:  2021-05-18       Impact factor: 7.867

Review 4.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577

5.  Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.

Authors:  Jotam G Pasipanodya; Deborah Ogbonna; Beatriz E Ferro; Gesham Magombedze; Shashikant Srivastava; Devyani Deshpande; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 6.  Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Keira A Cohen; Gyanu Lamichhane
Journal:  Front Microbiol       Date:  2018-09-25       Impact factor: 5.640

7.  Antimicrobial Susceptibility of Mycobacterium abscessus Complex Clinical Isolates from a Chinese Tertiary Hospital.

Authors:  Yinjuan Guo; Xingwei Cao; Jingyi Yu; Qing Zhan; Jinghui Yang; Xiaocui Wu; Baoshan Wan; Yin Liu; Fangyou Yu
Journal:  Infect Drug Resist       Date:  2020-06-26       Impact factor: 4.003

8.  Molecular epidemiology and phylogenomic analysis of Mycobacterium abscessus clinical isolates in an Asian population.

Authors:  Ka Lip Chew; Sophie Octavia; Roland Jureen; Oon Tek Ng; Kalisvar Marimuthu; Raymond Tzer Pin Lin; Jeanette W P Teo
Journal:  Microb Genom       Date:  2021-11

9.  In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics.

Authors:  Yaojie Shen; Xuyang Wang; Jialin Jin; Jing Wu; Xuelian Zhang; Jiazhen Chen; Wenhong Zhang
Journal:  Biomed Res Int       Date:  2018-12-30       Impact factor: 3.411

10.  Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease.

Authors:  Jianhui Chen; Lan Zhao; Yanhua Mao; Meiping Ye; Qi Guo; Yongjie Zhang; Liyun Xu; Zhemin Zhang; Bing Li; Haiqing Chu
Journal:  Front Microbiol       Date:  2019-08-23       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.